As we announced earlier, Boehringer Ingelheim, the German company would establish a new separate business for the development and commercialization of own biosimilars.
Now, according to the information on ClinicalTrials.gov, it seems Boehringer’s studies for biosimilars are already at a certain point.
The Phase I study of BI 695501 will be a Pharmacokinetics and Safety Study which will be conducted against Adalimumab. Adalimumab, which is marketed as Humira is one the blockbusters in rheumatoid arthritis treatment.
The arms of the study will be BI 695501 against EU version of adalimumab and the third arm will also be the US version of the same originator. You can find more information about the study from the below link: